Skip to main content

Table 1 Listings of infections with overall incidence in > 5% of patients with PTCL or CTCL

From: Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma

  Total AEs Drug-related AEs
Subgroup All grade grade ≥ 3 All grade Grade ≥ 3
Cellulitis, n (%)     
 PTCL 6 (5) 5 (4) 3 (2) 3 (2)
 CTCL 2 (2) 0 0 0
Pneumonia, n (%)
 PTCL 8 (6) 6 (5) 2 (2) 2 (2)
 CTCL 1 (0) 0 0 0
Sepsis, n (%)     
 PTCL 7 (5) 7 (5) 2 (2) 2 (2)
 CTCL 4 (4) 4 (4) 2 (2) 2 (2)
Nasopharyngitis, n (%)   
 PTCL 6 (5) 0 0 0
 CTCL 4 (4) 0 0 0
Upper respiratory tract infection, n (%)   
 PTCL 11 (8) 2 (2) 7 (5) 2 (2)
 CTCL 6 (6) 0 1 (1) 0
Urinary tract infection, n (%)   
 PTCL 9 (7) 1 (1) 2 (2) 1 (1)
 CTCL 3 (3) 0 1 (1) 0
Skin infection, n (%)   
 PTCL 2 (2) 0 1 (1) 0
 CTCL 7 (7) 1 (1) 2 (2) 0
  1. AE, adverse event; CTCL, cutaneous T-cell lymphoma; PTCL, peripheral T-cell lymphoma.